v3.22.2.2
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenue:        
Research and development $ 1,062,500 $ 2,125,000 $ 33,333
Costs and expenses:        
Research and development 3,706,828 4,621,255 12,811,462 10,343,451
General and administrative 2,818,252 2,256,689 8,423,868 7,710,625
Total costs and expenses 6,525,080 6,877,944 21,235,330 18,054,076
Loss from operations (5,462,580) (6,877,944) (19,110,330) (18,020,743)
Sale of New Jersey net operating loss & tax credits 1,734,133 1,328,470
Other income, net 988 41,394 13,748 108,298
Net loss (5,461,592) (6,836,550) (17,362,449) (16,583,975)
Preferred stock series B accumulated dividends (395,799)
Net loss attributable to common shareholders $ (5,461,592) $ (6,836,550) $ (17,362,449) $ (16,979,774)
Net loss available for common shareholders per share – basic and diluted $ (0.03) $ (0.03) $ (0.08) $ (0.08)
Weighted average common shares outstanding:        
Basic and diluted 216,864,526 215,179,949 216,792,083 208,130,431
Other comprehensive loss, net of tax        
Unrealized loss on securities available-for-sale $ (181,152) $ (52,837) $ (790,069) $ (229,766)
Other comprehensive loss, net of tax (181,152) (52,837) (790,069) (229,766)
Comprehensive loss attributable to shareholders $ (5,642,744) $ (6,889,387) $ (18,152,518) $ (16,813,741)

Source